{
    "id": 1166,
    "fullName": "PIK3CA amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA amplification indicates an increased number of copies of the PIK3CA gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "amp",
    "createDate": "07/27/2014",
    "updateDate": "04/29/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2478,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II study, MK2206 increased stable disease to 12 months in a nasopharyngeal carcinoma patient with Pik3ca amplification (PMID: 26084990).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 9261,
                "name": "nasopharynx carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3155,
                    "pubMedId": 26084990,
                    "title": "Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26084990"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10703,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ovarian cancer cell line harboring PIK3CA E545K was sensitive to XL765 (SAR245409), demonstrating inhibition of cell proliferation in culture, and inhibition of tumor growth in cell line xenograft models (PMID: 24634413).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1051,
                "therapyName": "SAR245409",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8768,
                    "pubMedId": 24634413,
                    "title": "Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24634413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19268,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Rigosertib (ON 01910.Na) treatment resulted in a complete response with disappearance of mediastinal and lung disease in a patients with head and neck squamous cell carcinoma harboring PIK3CA amplification (Cancer Res April 15 2013 (73) (8 Supplement) LB-198).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1046,
                "therapyName": "Rigosertib Sodium",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8903,
                    "pubMedId": null,
                    "title": "Abstract LB-198: Phase I and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors.",
                    "url": "http://cancerres.aacrjournals.org/content/73/8_Supplement/LB-198.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 4713,
                "therapyName": "Linsitinib + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6624,
                    "pubMedId": 27196766,
                    "title": "Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11508,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AZD8055 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1519,
                "therapyName": "AZD8055",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15771,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung squamous cell carcinoma a patient-derived xenograft (PDX) model harboring PIK3CA amplification, without additional PIK3CA mutations, did not respond to Buparlisib (BKM120) treatment (PMID: 30093452).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3914,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) enhanced the effects of radiation induced apoptosis in HNSCC cell lines and cell line xenograft models with PIK3CA amplification (PMID: 26589432).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 3967,
                "therapyName": "Radiotherapy + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4291,
                    "pubMedId": 26589432,
                    "title": "Taselisib (GDC-0032), a Potent \u03b2-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26589432"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11510,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 resulted in antiproliferative activity in head and neck squamous cell carcinoma cells harboring PIK3CA amplification in culture (PMID: 28446642).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9596,
                    "pubMedId": 28446642,
                    "title": "Cotargeting mTORC and EGFR Signaling as a Therapeutic Strategy in HNSCC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28446642"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8346,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NVP-AEW541 enhanced sensitivity of PIK3CA amplified triple-receptor negative breast cancer cells to Pictilisib (GDC-0941) in culture (PMID: 27196766).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 4046,
                "therapyName": "NVP-AEW541 + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6624,
                    "pubMedId": 27196766,
                    "title": "Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2819,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Panulisib (P7170) downregulated mTOR pathway signaling in ovarian cancer cells with amplified PIK3CA (PMID: 25700704).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 857,
                "therapyName": "Panulisib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3487,
                    "pubMedId": 25700704,
                    "title": "P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25700704"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6312,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited PI3K signaling and proliferation of a PIK3CA amplified human ovarian cancer cell line in culture, and inhibited tumor growth in xenograft models (PMID: 25637314).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12542,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) and Gemzar (gemcitabine) combination treatment resulted in inhibition of Akt phosphorylation and improved tumor growth inhibition and survival compared to single agent therapy in patient-derived xenograft (PDX) models of PIK3CA amplified bladder cancer (PMID: 28808038).",
            "molecularProfile": {
                "id": 1191,
                "profileName": "PIK3CA amp"
            },
            "therapy": {
                "id": 6490,
                "therapyName": "Gemcitabine + Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 11054,
                "name": "urinary bladder cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9961,
                    "pubMedId": 28808038,
                    "title": "The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28808038"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2143,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells harboring PIK3CA G1049R, KRAS G12D, and amplification of PIK3CA in culture (PMID: 22662154).",
            "molecularProfile": {
                "id": 5398,
                "profileName": "KRAS G12D PIK3CA G1049R PIK3CA amp"
            },
            "therapy": {
                "id": 2619,
                "therapyName": "BEZ235 + PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 348,
                    "pubMedId": 22662154,
                    "title": "Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22662154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2142,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BEZ235 and the MEK1 inhibitor PD98509 worked synergistically or additively to inhibit growth of endometrial cancer cells with amplification of PIK3CA and KRAS in culture (PMID: 22662154).",
            "molecularProfile": {
                "id": 5417,
                "profileName": "KRAS amp PIK3CA amp"
            },
            "therapy": {
                "id": 2619,
                "therapyName": "BEZ235 + PD98059",
                "synonyms": null
            },
            "indication": {
                "id": 1380,
                "name": "endometrial cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 348,
                    "pubMedId": 22662154,
                    "title": "Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22662154"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8344,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, shRNA knock-down of Igf1r in PIK3CA amplified triple-receptor negative breast cancer cells enhanced cell sensitivity to Pictilisib (GDC-0941) in culture (PMID: 27196766).",
            "molecularProfile": {
                "id": 26242,
                "profileName": "IGF1R dec exp PIK3CA amp"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6624,
                    "pubMedId": 27196766,
                    "title": "Sensitizing Triple-Negative Breast Cancer to PI3K Inhibition by Cotargeting IGF1R.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15782,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable responses in 2 of 3 lung squamous cell carcinoma patient-derived xenograft (PDX) models harboring PIK3CA E545K and PIK3CA amplification (PMID: 30093452).",
            "molecularProfile": {
                "id": 31215,
                "profileName": "PIK3CA E545K PIK3CA amp"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15789,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) treatment resulted in response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PIK3CA amplification (PMID: 30093452).",
            "molecularProfile": {
                "id": 31218,
                "profileName": "PIK3CA E542K PIK3CA amp"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15783,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Buparlisib (BKM120) treatment resulted in inhibition of AKT and S6 phosphorylation and durable response in a lung squamous cell carcinoma patient-derived xenograft (PDX) model harboring PIK3CA E542K and PIK3CA amplification (PMID: 30093452).",
            "molecularProfile": {
                "id": 31218,
                "profileName": "PIK3CA E542K PIK3CA amp"
            },
            "therapy": {
                "id": 680,
                "therapyName": "Buparlisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15798,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in patient-derived xenograft (PDX) models of lung squamous cell carcinoma harboring PIK3CA E545K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31223,
                "profileName": "CDKN2A loss PIK3CA E545K PIK3CA amp"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15800,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with the combination of Buparlisib (BYL719) and Ibrance (palbociclib) resulted in increased tumor growth inhibition compared to either agent alone in a patient-derived xenograft (PDX) model of lung squamous cell carcinoma harboring PIK3CA E542K and PIK3CA amplification, with p16 (CDKN2A) loss (PMID: 30093452).",
            "molecularProfile": {
                "id": 31224,
                "profileName": "CDKN2A loss PIK3CA E542K PIK3CA amp"
            },
            "therapy": {
                "id": 7736,
                "therapyName": "Buparlisib + Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 13808,
                    "pubMedId": 30093452,
                    "title": "Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093452"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16190,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent high-grade serous ovarian cancer harboring a TP53 I195T mutation and amplifications of ERBB2, CCNE1, PIK3CA, and SMARCA4 was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for approximately seven months, followed by Mektovi (binimetinib) alone for two months, and was progression-free at four years post-therapy (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 31513,
                "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17746,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (ExteNET), Nerlynx (neratinib) treatment resulted in improved 5-year invasive disease-free survival (92.4% vs 84.5%, HR=0.41, p=0.028) and clinical benefit (HR=0.40, p=0.041) compared to placebo in patients with ERBB2 (HER2)-positive early breast cancer who completed trastuzumab-based adjuvant therapy, and harbored PIK3CA amplification (n=61) or mutations (n=210), including H1047R (n=110), E542K (n=18), and E545K/D (n=82) (PMID: 30867034; NCT00878709).",
            "molecularProfile": {
                "id": 32788,
                "profileName": "ERBB2 pos PIK3CA amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15759,
                    "pubMedId": 30867034,
                    "title": "PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30867034"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification demonstrated resistance to treatment with Capmatinib (INC280) and were subsequently found to have acquired amplification of PIK3CA in culture (PMID: 30309221).",
            "molecularProfile": {
                "id": 35557,
                "profileName": "MET amp PIK3CA amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification and acquisition of PIK3CA amplification demonstrated sensitivity to the combination therapy of Piqray (alpelisib) and Capmatinib (INC280) in culture, resulting in decreased cell proliferation (PMID: 30309221).",
            "molecularProfile": {
                "id": 35557,
                "profileName": "MET amp PIK3CA amp"
            },
            "therapy": {
                "id": 9561,
                "therapyName": "Alpelisib + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1191,
            "profileName": "PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5398,
            "profileName": "KRAS G12D PIK3CA G1049R PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 5417,
            "profileName": "KRAS amp PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26242,
            "profileName": "IGF1R dec exp PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31215,
            "profileName": "PIK3CA E545K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31218,
            "profileName": "PIK3CA E542K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31223,
            "profileName": "CDKN2A loss PIK3CA E545K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31224,
            "profileName": "CDKN2A loss PIK3CA E542K PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31513,
            "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32788,
            "profileName": "ERBB2 pos PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35557,
            "profileName": "MET amp PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}